CN109925331A - 一种花生茎叶提取物及其制备方法与应用 - Google Patents
一种花生茎叶提取物及其制备方法与应用 Download PDFInfo
- Publication number
- CN109925331A CN109925331A CN201910317004.5A CN201910317004A CN109925331A CN 109925331 A CN109925331 A CN 109925331A CN 201910317004 A CN201910317004 A CN 201910317004A CN 109925331 A CN109925331 A CN 109925331A
- Authority
- CN
- China
- Prior art keywords
- stem leaf
- peanut stem
- preparation
- leaf extract
- peanut
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000017060 Arachis glabrata Nutrition 0.000 title claims abstract description 72
- 235000010777 Arachis hypogaea Nutrition 0.000 title claims abstract description 72
- 235000018262 Arachis monticola Nutrition 0.000 title claims abstract description 72
- 235000020232 peanut Nutrition 0.000 title claims abstract description 72
- 239000000284 extract Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 241001553178 Arachis glabrata Species 0.000 title claims abstract 16
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims abstract description 22
- 230000007958 sleep Effects 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims abstract description 12
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims abstract description 12
- 229940114124 ferulic acid Drugs 0.000 claims abstract description 12
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000001785 ferulic acid Nutrition 0.000 claims abstract description 12
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims abstract description 11
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims abstract description 11
- 229930007744 linalool Natural products 0.000 claims abstract description 11
- 238000003809 water extraction Methods 0.000 claims abstract description 9
- 239000003595 mist Substances 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 238000003306 harvesting Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- PACBGANPVNHGNP-RUDMXATFSA-N 2'-O-methylisoliquiritigenin Chemical compound COC1=CC(O)=CC=C1C(=O)\C=C\C1=CC=C(O)C=C1 PACBGANPVNHGNP-RUDMXATFSA-N 0.000 claims description 5
- PACBGANPVNHGNP-UHFFFAOYSA-N 3-deoxysappanchalcone Natural products COC1=CC(O)=CC=C1C(=O)C=CC1=CC=C(O)C=C1 PACBGANPVNHGNP-UHFFFAOYSA-N 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- -1 emplastrum Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 241000723346 Cinnamomum camphora Species 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002274 desiccant Substances 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 5
- 239000011149 active material Substances 0.000 abstract description 5
- 206010022437 insomnia Diseases 0.000 abstract description 5
- 235000008718 isoliquiritigenin Nutrition 0.000 abstract description 5
- 229920003266 Leaf® Polymers 0.000 description 58
- 244000105624 Arachis hypogaea Species 0.000 description 56
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 16
- 239000000126 substance Substances 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 210000003625 skull Anatomy 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 230000000975 bioactive effect Effects 0.000 description 5
- 230000005714 functional activity Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000003479 dental cement Substances 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- CKEXCBVNKRHAMX-UHFFFAOYSA-N (-)-naringenin 4',7-dimethyl ether Natural products C1=CC(OC)=CC=C1C1OC2=CC(OC)=CC(O)=C2C(=O)C1 CKEXCBVNKRHAMX-UHFFFAOYSA-N 0.000 description 2
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N methyl monoether Natural products COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940117954 naringenin Drugs 0.000 description 2
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 2
- 235000007625 naringenin Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 230000036578 sleeping time Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003106 tissue adhesive Substances 0.000 description 2
- 238000004804 winding Methods 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003084 Areflexia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 244000276331 Citrus maxima Species 0.000 description 1
- 235000001759 Citrus maxima Nutrition 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000002566 electrocorticography Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 1
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003183 myoelectrical effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种花生茎叶提取物及其制备方法与应用,所述花生茎叶提取物至少包含柚皮素‑4,7’‑二甲醚,2’‑O‑甲基异甘草素,芳樟醇,阿魏酸。所述的花生茎叶提取物差采用如下方式制得,将干燥的花生茎叶粉碎至微粉级别,然后采用水提法进行提取;其中,所述水提法具体为:将粉碎后的花生茎叶置于温度为75~85℃的水中4~5小时。本发明提供所提供的制备方法,可高效的提取花生茎叶中的活性物质,该花生茎叶提取物可有效改善睡眠,治疗失眠。
Description
技术领域
本发明属于功能营养食品领域,具体涉及一种花生茎叶提取物及其制备方法与应用。
背景技术
据不完全统计,失眠以及睡眠问题困扰着全世界人口,我国也有近2/3的居民存在着不同程度的睡眠问题。
随着生活节奏的加快,失眠人口的增多,对于治疗失眠、改善睡眠的药品,食品和保健品一直源源不断地涌现。但是由于传统西药的神经依赖性等毒副作用,传统中药的治疗效率低下,功效成分不明等缺点,我国以及全球市场上,公众接受度高,功效成分明确,睡眠改善效率高的促睡眠产品一直缺乏。
基于《滇南本草》、《浙江药用植物志》和《中药大辞典》等著名药典对花生茎叶治疗失眠功效的记载和六百余年的中医实践基础,以及我国具有绝对优势的花生产业现状,本专利论述了一种具有高含量促睡眠功效成分的花生茎叶提取物制备方法,依托系统地动物实验模型、高分辨率液质联用技术和先进的电生理技术对该方法所制备出的花生茎叶提取物进行了物质组成分析,功效成分筛选以及确证研究,最终确定了所制备的花生茎叶提取物促睡眠活性物质含量高和作用效果明确的特点。
因此拓宽改善睡眠、治疗失眠的产品、药品,提高我国居民的睡眠健康水平以及为我国传统中草药的药用和功能活性成分鉴定和功效确证提供新的思路具有十分重要和深远的意义。
发明内容
本发明的目的在于提供一种花生茎叶提取物,所述花生茎叶提取物至少包含柚皮素-4,7’-二甲醚,2’-O-甲基异甘草素,芳樟醇和阿魏酸。
本发明通过提取分离得到含有高含量的促进睡眠功能的活性物质;依托高分辨率液质联用技术鉴定出其中具有促睡眠功能活性潜力的柚皮素-4’,7-二甲醚,2’-O-甲基异甘草素,阿魏酸,芳樟醇的花生茎叶提取物;
其中,所述柚皮素-4,7’-二甲醚的含量不低于110mg/kg;
所述2’-O-甲基异甘草素的含量不低于32mg/kg;
所述芳樟醇的含量不低于44mg/kg;
所述阿魏酸的含量不低于175mg/kg。
优选的,所述柚皮素-4,7’-二甲醚的含量为114.75±3.42mg/kg;所述2’-O-甲基异甘草素的含量为32.40±0.02mg/kg;所述芳樟醇的含量为44.44±0.37mg/kg;所述阿魏酸的含量为189.86±11.40μg/kg。
本发明的又一目的在于提供上述花生茎叶提取物的制备方法,具体为:将干燥的花生茎叶粉碎至微粉级别,然后采用水提法进行提取。
为了提高提取率,及其所提活性物质的浓度,本发明在优化水提法的基础上,进一步提高其条件和参数。
其中,本发明优选采用收获期的茎叶,尤其是青色未枯状态的茎叶;并在选用该种状态茎叶的基础上,优化其提取的方式。
其中,所述水提法具体为:将粉碎后的花生茎叶置于温度为75~85℃的水中4~5小时。
其中,所述微粉级别具体的,将所述干燥后的花生茎叶进行超微粉碎,使物料颗粒的粒径为1-100μm。
本发明优选的,所述干燥具体为:将新鲜花生茎叶干燥至水分含量为10%~15%。
更优选的,所述干燥采用自然干燥的方式。如,将收获期的新鲜花生茎叶摘选,洗净后于通风日照处晾晒。
本发明优选的,所述花生茎叶与所述水的料液比(重量比)为10~20:1。
本发明优选的,所述水提法中,循环1~4次;优选为2次。即在该温度下提取4~5小时循环2次。
其中,所述提取结束后,还包括干燥,具体为可以为低温减压干燥,进一步优选为:将双效浓缩后的提取物药液至于干燥剂物料板上,在温度40~50℃,真空度为-0.1~-0.5Mpa下干燥24-48h。
本发明提供一种优选方案,所述制备方法包括如下步骤:
1)将新鲜花生茎叶干燥至水分含量为10%~15%,然后将干燥的花生茎叶粉碎至微粉级别;
2)将粉碎后的花生茎叶按料液比为10~20:1的比例,加入温度为75~85℃的水中,提取4~5小时,将步骤2)循环2次;
3)采用负压低温干燥机对步骤2)提取液进行干燥,干燥箱温度控制在40~50℃,真空度为-0.1~-0.5Mpa。
本发明还提供一种药物组合物或者保健品组合物,以上述的花生茎叶提取物为活性物质,加入常规辅料制成大众消费群体可接受的剂型。
优选的,所述剂型可为片剂、胶囊剂、散剂、合剂、丸剂、颗粒剂、糖浆剂、贴膏剂、栓剂、气雾剂、软膏剂或注射剂中的一种。
所添加的辅料为填充剂、崩解剂、润滑剂、助悬剂、粘合剂、甜味剂、矫味剂、防腐剂、基质中的一种或多种。
其中,所述填充剂包括:淀粉、预胶化淀粉、乳糖、甘露醇、甲壳素、微晶纤维素、蔗糖等;
其中,所述崩解剂包括:淀粉、预胶化淀粉、微晶纤维素、羧甲基淀粉钠、交联聚乙烯吡咯烷酮、低取代羟丙纤维素、交联羧甲基纤维素纳等;
其中,所述润滑剂包括:硬脂酸镁、十二烷基硫酸钠、滑石粉、二氧化硅等;
其中,所述助悬剂包括:聚乙烯吡咯烷酮、微晶纤维素、蔗糖、琼脂、羟丙基甲基纤维素等;
其中,所述粘合剂包括,淀粉浆、聚乙烯吡咯烷酮、羟丙基甲基纤维素等;
其中,所述甜味剂包括:糖精钠、阿斯帕坦、蔗糖、甜蜜素、甘草次酸等;
其中,所述矫味剂包括:甜味剂及各种香精;
其中,所述防腐剂包括:尼泊金类、苯甲酸、苯甲酸钠、山梨酸及其盐类、苯扎溴铵、醋酸氯乙定、桉叶油等;基质包括:P E G 6 0 0 0、PEG4000、虫蜡等。
本发明提供的所述花生茎叶提取物以及所述药物组合物或者保健品组合物在促进睡眠上的具有显著的应用。可有效改善睡眠,治疗失眠。
本发明以BAL b/c小鼠为模型,采用电生理技术,在小鼠脑部植入电极,实时监控给药后小鼠14天*24小时脑波变化,从而最终确定了本发明提供的花生茎叶提取物在的功能活性物质具有显著地促睡眠功能。
附图说明
图1为实验例1中四种生物活性物质LC-MS定量图谱;
图2为实验例2中花生茎叶提取物对小鼠24小时睡眠时间的影响情况图;
图3为实验例2中四种功能活性物质对小鼠24小时睡眠的影响情况图。
具体实施方式
以下实施例用于说明本发明,但不用来限制本发明的范围。
实施例1
本实施例提供一种花生茎叶提取物的制备方法,具体为:
1)将收获期新鲜的花生茎叶摘选,洗净后于通风日照处晾晒,干燥至水分含量为10%~15%,然后将干燥的花生茎叶进行超微粉碎,使物料颗粒粒径在1~100μm;
2)取100g粉碎完的花生茎叶粉末,加入10倍重量的水置于提取罐中进行提取,提取温度为80-85℃,提取时间为4-5小时,循环次数2次;
3)采用负压低温干燥机对提取液进行干燥,干燥箱温度控制在40~50℃,真空度为-0.1~-0.5Mpa。
经计算,本实施例制备的花生茎叶提取物的提取率为21.8%。
实施例2
本实施例提供过一种花生茎叶提取物的制备方法,具体为:
1)将收获期新鲜的花生茎叶摘选,洗净后于通风日照处晾晒,干燥至水分含量为10%~15%,然后将干燥的花生茎叶进行超微粉碎,使物料颗粒粒径在1~100μm;
2)取100g粉碎完的花生茎叶粉末,加入15倍重量的水置于提取罐中进行提取,提取温度为80-85℃,提取时间为4-5小时,循环次数2次;
3)采用负压低温干燥机对提取液进行干燥,干燥箱温度控制在40~50℃,真空度为-0.1~-0.5Mpa。
经计算,本实施例制备的花生茎叶提取物的提取率为25.8%。
实施例3
本实施例提供过一种花生茎叶提取物的制备方法,具体为:
1)将收获期新鲜的花生茎叶摘选,洗净后于通风日照处晾晒,干燥至水分含量为10%~15%,然后将干燥的花生茎叶进行超微粉碎,使物料颗粒粒径在1~100μm;
2)取100g粉碎完的花生茎叶粉末,加入20倍重量的水置于提取罐中进行提取,提取温度为80-85℃,提取时间为4-5小时,循环次数2次;
3)采用负压低温干燥机对提取液进行干燥,干燥箱温度控制在40~50℃,真空度为-0.1~-0.5Mpa。
经计算,本实施例制备的花生茎叶提取物的提取率为22.1%。
实施例4
本实施例提供过一种花生茎叶提取物的制备方法,与实施例1的区别仅在于,“收获期的花生茎叶”替换为“生长期后期的青嫩花生茎叶”。
本实施例制备的花生茎叶提取物的提取率为15%。
实施例5
本实施例提供过一种花生茎叶提取物的制备方法,与实施例1的区别仅在于,采用喷雾干燥设备对提取液进行干燥。本实施例的花生茎叶提取物提取率在20%-25%。
但经检测花生茎叶提取物中所含功能活性物质的含量显著降低,分别为:柚皮素-4,7’-二甲醚的含量85mg/kg;2’-O-甲基异甘草素的含量24mg/kg;所述芳樟醇的含量不低于12mg/kg;和/或,所述阿魏酸的含量154mg/kg。
实施例6
本实施例提供过一种花生茎叶提取物的制备方法,与实施例1的区别仅在于,在干燥环节采用真空冷冻干燥。本实施例的花生茎叶提取物的提取率和四种生物活性物质的含量无明显变化,但干燥时间增加至48-72小时。
实验例1
1、将实施例1制得的花生茎叶提取物采用如下方式鉴定生物活性物质,具体为:
1)分部位提取:称取10g的花生茎叶水提物粉末分别用乙酸乙酯、石油醚(40℃~60℃)、正丁醇索氏提取。提取后,收集溶剂,用真空旋转蒸发器减压旋蒸至几近全干。取25ml色谱级乙腈予以复溶,用锡箔纸包裹后,-80℃超低温冷冻贮藏,待用;
2)活性物质鉴定采用UPLC-QTOF-MS检测设备和UNIFI数据分析平台分析不同提取方式得到的提取物的物质组成。柱温45℃,样品温度5℃;水(含0.1%甲酸)作为流动相A相,乙腈(含0.1%甲酸)作为流动相B相;进样流速0.6ml/min,进样量10μL;弱洗液:90/10(水/乙腈),每次灌柱600μL;
洗脱梯度见下表
表1
选择正离子和灵敏度分析模式进行QTOF-MS数据采集;离子质荷比范围为m/z 50-1000;电晕电压为2.1kV,锥孔电压为40V,离子源温度为120℃,碰撞能15到45V。选择MSE全扫描数据采集模式,扫描时间间隔为0.2秒。
实施例1所制备的花生茎叶提取物中生物活性物质信息,包括139中生物活性物质。
2、对功能活性物质的含量采用如下方法进行定量检测。
将制备的花生茎叶水提物粉末用纯水溶解,浓度根据对应高分辨率质谱的建议进样浓度确定,原则上不高于1mg/kg。采用高分辨率和准确性的气相/超高效液相色谱串联三重四级杆质谱定量分析花生茎叶中柚皮素-4,7’-二甲醚、2’-O-甲基异甘草素、阿魏酸和芳樟醇的含量。为充分保证检测结果的准确性和可信度,试验采用气质联用(GC-QQQ-MS)测定芳樟醇的含量,采用液质联用(UHPLC-QQQ-MS)测定柚皮素-4,7’-二甲醚、2’-O-甲基异甘草素和阿魏酸的含量。方法的选择主要依据化合物的挥发性和气/液质联用仪的鉴定原理。因为芳樟醇的高挥发性,故试验采用GC-MS对其进行了测定。相关的检测参数如下表所示,以及四种功能性活性物质的含量。
表2
如图1所示,四种生物活性物质LC-MS定量图谱(A:柚皮素-4’,7-二甲醚,B:2’-O-甲基异甘草素,C:阿魏酸,D:芳樟醇)
实验例2
实施例1中所制备的花生茎叶提取物对小鼠睡眠的影响实验
一、实验材料
1mL注射器(江苏宇阳医疗器械有限公司);Sleepsign睡眠分析软件(日本KisseiComtec株式会社);不锈钢小螺丝M1.0*2(哈利路亚精密金属制品有限公司);MP150多导生理信号记录分析系统(美国Biopac公司);小鼠适配器(深圳市瑞沃德生命科技有限公司);高速颅骨钻(深圳市瑞沃德生命科技有限公司);牙科水泥(上海二医张江生物材料有限公司);义齿基托树脂(上海二医张江生物材料有限公司);记录排线和电极(东莞市耀博电子有限公司);组织胶(日本Toagosei公司);其相关试剂(日本TaKaRa公司);电极用银丝(美国Cooner Wire公司)。
二、实验方法
1.供试药物
按照实施例1的方法制备花生茎叶提取物作为实验药物,并根据鉴定出来柚皮素-4’,7-二甲醚等物质含量对小鼠进行标准品给药
2.实验动物及分组
实验共分为对照组、提取物组(低、中、高剂量三组)、阳性对照组、功能因子组(四种功能活性物质),采用雄性Bal b/c小鼠,每组6只
3.实验时间轴及具体步骤:
水合氯醛(4%)以0.10mL/10g对小鼠进行腹腔麻醉,待小鼠痛觉反射消失后,将其固定于小鼠脑立体定位适配器上,剪去小鼠头顶毛发,并用75%酒精消毒皮肤,沿颅骨正中线切开皮肤,分离皮下组织使颅骨充分暴露。于前颅前1.0mm且颅骨中线左侧旁开1.5mm处用颅骨钻钻一个孔打穿颅骨,在后囟前1.0mm与颅骨中线左侧旁开1.5mm处用颅骨钻钻通颅骨(注意不要弄破脑膜,钻头直径为0.8mm为宜,两个孔在颅骨中缝右侧亦可,但两个孔需在同侧),先后用组织胶和牙科水泥将脑电电极固定于颅骨上,脑电电极通过银丝连接螺丝(固定于颅骨钻打出的孔中)以触碰硬脑膜为度,用于记录皮层脑电活动。将两根肌电电极连接的银丝分别插入小鼠颈背部两侧的肌肉内,用于记录肌电活动。然后将电极底座用组织胶和牙科水泥固定于颅骨上。小鼠手术后注射青霉素(计量8万单位/天,连续三天)。小鼠手术后恢复期间放入恒温、恒湿、隔音和静电屏蔽功能的屏蔽箱内单独饲养,手术后第二天将记录脑电和肌电的排线与小鼠头部的电极连接并适应7天,屏蔽箱内光照8:00am~8:00pm。恢复并适应实验环境的小鼠早上8:00开始脑电肌电实验记录,记录24小时,这一天记作D0,此数据当做自身对照,然后从D1天到D14天早上八点之前灌胃给药,在D7和D14天记录一次脑电肌电,在D15天早上8:00灌胃之后取脑组织。
4.实验结果
如图2所示,花生茎叶提取物对小鼠24小时睡眠时间的影响;其中,125mg/kg(BW)、250mg/kg(BW)、500mg/kg(BW)的提取物均能显著增加小鼠的总睡眠时间,并且作用效果随给药时间、给药浓度的增加而提高。
如图3所示,四种功能活性物质对小鼠24小时睡眠的影响(YPS:柚皮素-4’,7-二甲醚,GCS:2’-O-甲基异甘草素,AWS:阿魏酸,GCS:甘草素);其中,柚皮素-4’,7-二甲醚,2’-O-甲基异甘草素,阿魏酸,芳樟醇均能显著提高小鼠睡眠时间。
虽然,上文中已经用一般性说明、具体实施方式及试验,对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (10)
1.一种花生茎叶提取物,其特征在于,至少包含柚皮素-4,7’-二甲醚,2’-O-甲基异甘草素,芳樟醇和阿魏酸。
2.根据权利要求1所述的花生茎叶提取物,其特征在于,所述柚皮素-4,7’-二甲醚的含量不低于110mg/kg;和/或,所述2’-O-甲基异甘草素的含量不低于32mg/kg;和/或,所述芳樟醇的含量不低于44mg/kg;和/或,所述阿魏酸的含量不低于175mg/kg。
3.一种花生茎叶提取物的制备方法,其特征在于,将干燥的花生茎叶粉碎至微粉级别,然后采用水提法进行提取;
其中,所述水提法具体为:将粉碎后的花生茎叶置于温度为75~85℃的水中4~5小时。
4.根据权利要求3所述的制备方法,其特征在于,所述花生茎叶为收获期的茎叶,所述茎叶为青色未枯状态。
5.根据权利要求4所述的制备方法,其特征在于,所述干燥具体为:将新鲜花生茎叶干燥至水分含量为10%~15%;
更优选的,所述干燥采用自然干燥的方式。
6.根据权利要求4或5所述的制备方法,其特征在于,所述花生茎叶与所述水的料液比为10~20:1。
7.根据权利要求4~6任一项所述的制备方法,其特征在于,所述水提法中,循环1~4次;优选为2次。
8.根据权利要求4~7任一项所述的制备方法,其特征在于,所述提取结束后,还包括干燥,具体为:将提取物药液置于干燥剂物料板上,在温度40~50℃,真空度为-0.1~-0.5Mpa下干燥。
9.权利要求1或2所述花生茎叶提取物在促进睡眠的药品或保健品上的应用。
10.根据权利要求9所述的应用,其特征在于,所述药品或保健品为片剂、胶囊剂、散剂、合剂、丸剂、颗粒剂、糖浆剂、贴膏剂、栓剂、气雾剂、软膏剂或注射剂中的一种。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910317004.5A CN109925331A (zh) | 2019-04-19 | 2019-04-19 | 一种花生茎叶提取物及其制备方法与应用 |
US16/627,728 US20220088103A1 (en) | 2019-04-19 | 2019-07-18 | Peanut stem and leaf extract and preparation method and use thereof |
PCT/CN2019/096533 WO2020211203A1 (zh) | 2019-04-19 | 2019-07-18 | 一种花生茎叶提取物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910317004.5A CN109925331A (zh) | 2019-04-19 | 2019-04-19 | 一种花生茎叶提取物及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109925331A true CN109925331A (zh) | 2019-06-25 |
Family
ID=66990447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910317004.5A Pending CN109925331A (zh) | 2019-04-19 | 2019-04-19 | 一种花生茎叶提取物及其制备方法与应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20220088103A1 (zh) |
CN (1) | CN109925331A (zh) |
WO (1) | WO2020211203A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020211203A1 (zh) * | 2019-04-19 | 2020-10-22 | 中国农业科学院农产品加工研究所 | 一种花生茎叶提取物及其制备方法与应用 |
CN116370581A (zh) * | 2023-05-08 | 2023-07-04 | 厚德科技(肇庆)有限公司 | 一种改善睡眠产品的配方及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010116385A2 (en) * | 2009-04-08 | 2010-10-14 | Rubicon Research Private Limited | Pharmaceutical compositions for alleviating unpleasant taste |
CN102579554A (zh) * | 2011-01-17 | 2012-07-18 | 天津药物研究院 | 花生茎叶提取物及其制备方法用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103181949A (zh) * | 2011-12-29 | 2013-07-03 | 天津药物研究院 | 一种镇静安神口服制剂及其制备方法 |
CN109925331A (zh) * | 2019-04-19 | 2019-06-25 | 中国农业科学院农产品加工研究所 | 一种花生茎叶提取物及其制备方法与应用 |
-
2019
- 2019-04-19 CN CN201910317004.5A patent/CN109925331A/zh active Pending
- 2019-07-18 US US16/627,728 patent/US20220088103A1/en not_active Abandoned
- 2019-07-18 WO PCT/CN2019/096533 patent/WO2020211203A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010116385A2 (en) * | 2009-04-08 | 2010-10-14 | Rubicon Research Private Limited | Pharmaceutical compositions for alleviating unpleasant taste |
CN102579554A (zh) * | 2011-01-17 | 2012-07-18 | 天津药物研究院 | 花生茎叶提取物及其制备方法用途 |
Non-Patent Citations (2)
Title |
---|
刘劲松: "花生茎叶不同提取部位对小鼠镇静催眠作用的初步探讨", 《中药材》 * |
邓磊: "花生茎叶提取物促睡眠活性物质鉴定及作用机制研究", 《中国优秀硕士学位论文全文数据库工程科技Ⅰ辑》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020211203A1 (zh) * | 2019-04-19 | 2020-10-22 | 中国农业科学院农产品加工研究所 | 一种花生茎叶提取物及其制备方法与应用 |
CN116370581A (zh) * | 2023-05-08 | 2023-07-04 | 厚德科技(肇庆)有限公司 | 一种改善睡眠产品的配方及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US20220088103A1 (en) | 2022-03-24 |
WO2020211203A1 (zh) | 2020-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ungerstedt | Postsynaptic supersensitivity after 6‐hydroxy‐dopamine induced degeneration of the nigro‐striatal dopamine system | |
Alamgir et al. | Pharmacognostical Botany: Classification of medicinal and aromatic plants (MAPs), botanical taxonomy, morphology, and anatomy of drug plants | |
US20200281845A1 (en) | Compositions comprising lespedeza plant extract | |
CN109925331A (zh) | 一种花生茎叶提取物及其制备方法与应用 | |
CN103127158B (zh) | 一种青钱柳提取物及其应用 | |
TWI284040B (en) | Herbal compositions for treating immunological disorders | |
CN105764519B (zh) | 用于治疗咳嗽的基于植物的组合物 | |
CN102305839A (zh) | 宣肺平喘的中药组合物的检测方法 | |
US11596664B2 (en) | Plant extracts made of Sideritis and use thereof to boost cognitive performance | |
CN104873554A (zh) | 辣木籽及其提取物在作为促进学习记忆的药物、保健食品 | |
CN102895438B (zh) | 石菖蒲提取物制备治疗老年痴呆症药物的用途 | |
CN104771451B (zh) | 一种具有抗抑郁作用的中药提取物及其应用 | |
Rahmi et al. | The activity of wungu leaf (Graptophyllum pictum (L) Griff) extract in reducing blood glucose level of hyperglycemic mice | |
CN104435072B (zh) | 一种具有辅助降血糖、降血脂的提取物及其制备方法 | |
CN104826086B (zh) | 具改善老年痴呆症作用的多肽组合物及其制备方法和应用 | |
CN109303785A (zh) | 一种党参炔苷类似化合物在制备治疗心率失常药物中的应用 | |
EP3019183B1 (en) | Reuptake inhibitors | |
CN109125362A (zh) | 刺蒺藜提取物在制备抗疲劳药物以及生物制品中的应用 | |
CN110101732A (zh) | 具有改善肠道功能的菊茎叶多成分颗粒剂及其制备方法与应用 | |
CN102895439B (zh) | 治疗痴呆症的石菖蒲提取物及其提取方法 | |
CN100545163C (zh) | 一种防治老年痴呆的中药活性成分化合物及其制备和用途 | |
CN111375012B (zh) | 一种抗抑郁的药物组合物和制备方法及其用途 | |
CN110812415B (zh) | 一种改善睡眠的益心宁神组合物的制备方法 | |
CN110151842A (zh) | 一种枇杷花黄酮提取物的应用及含有该提取物的组合物 | |
CN108272917A (zh) | 一种治疗记忆力减退的维吾尔药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190625 |